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AbstrACt
Introduction Our current ability to predict the course 
and outcome of early psychotic symptoms is limited, 
hampering timely treatment. To improve our understanding 
of the development of psychosis, a different approach 
to psychopathology may be productive. We propose 
to reconceptualise psychopathology from a network 
perspective, according to which symptoms act as a 
dynamic, interconnected system, impacting on each 
other over time and across diagnostic boundaries to form 
symptom networks. Adopting this network approach, the 
Mapping Individual Routes of Risk and Resilience study 
aims to determine whether characteristics of symptom 
networks can predict illness course and outcome of early 
psychotic symptoms.
Methods and analysis The sample consists of n=100 
participants aged 18–35 years, divided into four 
subgroups (n=4×25) with increasing levels of severity 
of psychopathology, representing successive stages of 
clinical progression. Individuals representing the initial 
stage have a relatively low expression of psychotic 
experiences (general population), whereas individuals 
representing the end stage are help seeking and display 
a psychometric expression of psychosis, putting them 
at ultra-high risk for transition to psychotic disorder. At 
baseline and 1-year follow-up, participants report their 
symptoms, affective states and experiences for three 
consecutive months in short, daily questionnaires on 
their smartphone, which will be used to map individual 
networks. Network parameters, including the strength 
and directionality of symptom connections and centrality 
indices, will be estimated and associated to individual 
differences in and within-individual progression through 
stages of clinical severity and functioning over the next 
3 years.
Ethics and dissemination The study has been 
approved by the local medical ethical committee (ABR 
no. NL52974.042.15). The results of the study will be 
published in (inter)national peer-reviewed journals, 
presented at research, clinical and general public 
conferences. The results will assist in improving and  
fine-tuning dynamic models of psychopathology, 
stimulating both clinical and scientific progress.
trial registration number NTR6205; Pre-results.
IntroduCtIon 
Psychotic disorders are among the most 
severe mental disorders in terms of individual 
and societal impact.1 2 Therefore, early detec-
tion and intervention in psychosis should 
be highly prioritised,3 which is increas-
ingly acknowledged.4 Psychosis is currently 
conceptualised as a continuum of psychotic 
severity, encompassing both subclinical and 
clinical expressions.5 As such, psychotic symp-
toms are present in the context of psychotic 
disorders and across other, non-psychotic 
disorders.6 7 
Current diagnostic systems in psychiatry 
are challenged by issues such as high levels 
strengths and limitations of this study
 ► One of the first studies examining the predictive 
potential of dynamic symptoms networks for the 
onset and progression of psychopathology.
 ► The study design allows considering within-
individual and between-individual variation in 
symptomatology, both at the micro (day) and macro 
(year) level.
 ► A dynamic, transdiagnostic approach is adopted; 
outcome measures include clinical stage, diagnosis, 
symptoms of a broad range of disorders and 
functioning.
 ► With annual follow-ups up to four years after 
baseline, we may not capture all transitions to 
psychosis.
 ► The exploratory nature of the study warrants 
replication of the findings.
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of comorbidity, clinical heterogeneity, non-specific treat-
ment effects and lack of diagnosis-specific biological/
cognitive markers.8–12 Despite this, traditional diagnoses 
still dominate psychiatric research, hampering scientific 
progress. These diagnoses are based on clinical presen-
tation of adults with long-established illness13 and classify 
individuals according to distinct diagnostic labels8 (eg, 
schizophrenia or major depressive disorder). However, 
it is increasingly acknowledged that psychopathology is 
expressed dimensionally, representing a quantitative as 
well as qualitative deviation from mental health.8 14–19 In 
addition, it is increasingly accepted that mental disor-
ders do not emerge fully formed in adulthood but evolve 
gradually, often manifesting for the first time already in 
adolescence.20 21
A model that was designed to capture this conti-
nuity of both severity and time is the clinical staging 
model.22 23 This model describes psychopathology as 
ranging, through subsequent but qualitatively different 
stages, from increased risk of mental illness at the lowest 
level to progressive stages of severity, resulting in sepa-
rable but overlapping syndromes at the highest levels.24 25 
Stage 0 represents individuals at increased risk without 
symptoms; stage 1a represents ‘help-seeking’ individuals 
with mild, non-specific symptoms; stage 1b represents 
individuals with an ‘attenuated syndrome’, with moderate 
but subthreshold symptoms and moderate functional 
decline; stage 2 holds individuals with a first episode of 
a clinical, ‘discrete’, disorder; stage 3 holds individuals 
with persistent or recurrent illness13 22 23 and stage 4 
represents individuals with chronic illness. This clinical 
staging model further hypothesises that psychopatho-
logical expression is more multidimensional, non-specific 
and more susceptible to intervention in early stages and 
becomes more crystallised, disorder specific and treat-
ment resistant in later stages.25 This model offers a theo-
retical representation that seems to fit better to the true 
nature and development of psychopathology9–11 26 and 
hence may improve diagnostic accuracy. It has been devel-
oped most extensively in the context of psychosis23 25 27 but 
needs further empirical validation. Longitudinal studies 
assessing predictive validity of the model have mostly 
concentrated around the transition from stage 1b (ultra-
high risk) to stage 2 (first psychotic episode) and found 
3-year transition rates of 36%.28 In addition, some biolog-
ical and cognitive measures seem to be more abnormal in 
more severe stages, and these measures seem to change 
in patients who progress in stage.29 30 Finally, some 
treatments seem more effective for individuals in early 
stages.30 Taken together, these studies provide at least 
some support for the clinical staging model of psychosis. 
However, many questions still remain, for example, about 
what drives progression through subsequent stages and 
how the thresholds between the stages should be defined 
exactly.
The expression and development of early psychotic 
symptoms are highly variable31–34 and difficult to 
predict.28 35 One reason for this is that many studies so 
far have focused on early psychotic symptoms as specific 
predictors of later schizophrenia. However, this approach 
may be too narrow25 33 36 because early psychotic symp-
toms are often transitory,37–39 also occur in the context 
of6 7 40–42 and predict other mental disorders28 37 43 44 and 
vice versa.45–47 High levels of comorbidity48 and overlap 
of risk factors49–52 also challenge the assumed indepen-
dence of psychosis from other symptom domains. In addi-
tion, the information that is used to predict course and 
outcome is often based on cross-sectional assessment of 
symptoms and comparisons are often made at the group 
level. However, symptoms can vary substantially over time, 
both over short (ie, days) and long intervals (months and 
years), within one individual and can also cross diag-
nostic borders.53 This means that the clinical picture can 
change, particularly in the early phase of a disorder.25 
These characteristics of psychopathology suggest that the 
‘static’ model prediction may not be fit for the purpose. 
This is reflected in the modest accuracy and replicability 
of static prediction models in the psychosis prediction 
field.54–56
The above-mentioned challenges may be overcome 
by taking a different approach towards the conceptuali-
sation of psychopathology, its measurement and the way 
we model it. By taking a more transdiagnostic approach, 
incorporating symptoms and experiences from multiple 
(psychotic and non-psychotic) domains, the narrow focus 
on the sole dimension of psychosis can be broadened. 
Furthermore, by modelling individual symptom patterns 
over time, a more developmental as well as a more person-
alised approach can be taken that, in addition, builds on 
a more detailed inventory of symptomatology compared 
with baseline (cross-sectional) assessment scores. Finally, 
modelling the interconnectivity between symptoms by 
mapping individual symptom networks and patterns of 
co-occurrence in and over time could provide us with a 
better idea of how psychopathology develops and may 
give us clues on what processes may drive progression 
through subsequent clinical stages.56 57
A network approach to psychopathology
A focus on dynamic symptom networks requires an inno-
vative approach to psychopathology. One of the currently 
promising alternative approaches comes from network 
theory. From this network perspective, psychopathology, 
at a phenomenological level, is hypothesised to result 
from interactions between symptoms.11 58 59 Mental disor-
ders are thus represented by sets of symptoms, connected 
in networks by causal relations11 58 (see also figure 1). 
These networks are dynamic and capture reciprocal influ-
ences between symptoms over time (eg, feedback loops). 
Importantly, symptoms are acknowledged as causal factors 
in psychopathological development: one symptom (eg, 
anxiety) can cause another (eg, paranoia). This is in sharp 
contrast with current dominant models that represent 
symptoms as independent indicators of underlying, latent 
constructs (eg, schizophrenia). As stress is important in the 
development of psychosis,60 61 the sensitivity of symptom 
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networks to risk-enhancing (trauma) and risk-reducing 
(coping and social support) factors62 63 also needs atten-
tion. The network approach has been successfully applied 
in other fields64 65 but is relatively novel in psychiatry, where 
it has been investigated mainly in common mental disor-
ders66 but not psychosis.
Aims and hypotheses
With the Mapping Individual Routes of Risk and Resilience 
(Mirorr) study, we aim to investigate the hypothesis of 
dynamic symptom networks as the basis of psychopathology 
in general and psychosis in particular. The key hypothesis 
to be tested centres on the question whether individual 
networks of a broad scope of transdiagnostic symptoms can 
predict course and outcome of early psychopathology in 
young individuals at increased risk for psychosis and other 
severe mental illness. Furthermore, we aim to investigate 
the additional hypothesis of symptom networks as markers/
indicators of progression of illness through successive 
clinical stages. Taking a broader, multidimensional and 
process-oriented approach, we will examine how symp-
toms of multiple domains influence each other over time 
and across diagnostic boundaries, in interaction with envi-
ronmental factors. More specifically, we hypothesise that 
different clinical stages will be characterised by different 
symptom networks. In addition, we expect that character-
istics of these networks can predict progression through 
clinical stages. We will explore the predictive potential of 
several characteristics, such as the strength and direction-
ality of symptom connections (see figure 1) and centrality 
indices (information about the position of a symptom in 
the network). Finally, we will evaluate the predictive poten-
tial of these characteristics against (more) static assessments 
of symptom severity.
The Mirorr study is unique in its design and in its attempt 
to (1) bring together a network approach to psychopa-
thology and the clinical staging model, (2) take a broader 
perspective on mental illness by (A) taking a transdiag-
nostic approach towards symptomatology and (B) defining 
outcome more broadly in the context of clinical staging 
(incorporating both clinical and functional outcomes) and 
(3) modelling individual symptom networks over time by 
using time-series data, enabling us to model more person-
alised pathways of psychopathological development.
outcome measures
Traditionally, research in the field of psychosis focuses 
mostly on transition from clinical high risk to a first 
episode of psychosis.67 However, there is growing aware-
ness that this may be arbitrary, especially in the context of 
a staging model that acknowledges expression of illness 
along a much broader severity spectrum. In addition, func-
tional outcome is becoming more and more an important 
outcome of interest, as it has been shown that both clin-
ical and functional outcomes are important but not always 
congruent.68–70 Working from a clinical staging perspec-
tive, important outcomes to investigate include therefore 




This study combines idiographic (within-person) and 
nomothetic (between-person) observational study 
designs. The nomothetic aspect of the study is captured 
by questionnaire and interview data at baseline and 
3 yearly follow-up measurement waves. Among other 
Figure 1 Parameters of a theoretical symptom network. Note: this figure is for illustrative purposes and is not based on real 
data.
group.bmj.com on February 13, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
4 Booij SH, et al. BMJ Open 2018;8:e019059. doi:10.1136/bmjopen-2017-019059
Open Access 
things, symptomatology, functioning and need for care 
will be assessed (outcome measures), as well as risk and 
protective factors. The idiographic aspect is captured by 
diary assessments at baseline and the first follow-up wave. 
During the diary periods, participants will complete a 
diary questionnaire daily for a period of 90 days on their 
smartphone regarding symptoms, emotions, functioning 
and stress. These diary data are used to map individual 
symptom networks. For the second diary period, partic-
ipants can also opt to keep continuing the question-
naire follow-ups but not have a second diary period. A 
flow chart of the study is presented in figure 2.
study population
The total sample comprises 175 individuals of 18–35 years, 
whereof 100 will enter the main study (ie, the daily diary 
study and the yearly follow-ups). For the main study, there 
will be four subsamples, all n=25 (figure 3) with each 
subgroup, having an increasingly more severe psycho-
pathological level and thus representing subsequent 
clinical stages. For subsample 1 (lowest level of psychopa-
thology and thus lowest clinical stage), 100 individuals will 
be randomly selected from the general population in the 
north of the Netherlands and administered the Commu-
nity Assessment of Psychic Experiences (CAPE).71 Of all 
the respondents who meet the inclusion and exclusion 
criteria of the study, the highest scoring quartile will be 
included in the main study. For subsamples 2–4, individ-
uals will be recruited from mental healthcare institutions 
in the four northern provinces in The Netherlands. For 
all individuals who are referred to mental healthcare, 
psychotic symptoms are routinely screened by means 
of, among other things, the Prodromal Questionnaire 
(PQ).72 If the score on the PQ is 6 or higher, the Compre-
hensive Assessment of At Risk Mental State (CAARMS)73 
is administered as well. With these scores, it is determined 
for which subsample (2–4, explained below) eligible 
subjects will be recruited, where a higher subsample indi-
cates higher levels of psychopathology.
In order to be eligible to participate in the study, subjects 
must meet all of the following criteria: (1) aged between 
18 and 35 years, (2) read and speak Dutch fluently, (3) 
capable of following the research procedures and (4) 
provide informed consent. In addition, participants of 
subsample 1 should not be in clinical care for mental 
health at the moment of screening. In contrast, partic-
ipants of subsamples 2–4 should currently be in clinical 
care for mental health. In addition, participants of subsa-
mple 2 should have mild, non-psychotic psychopathology, 
as evidenced by a score below 6 on the PQ, participants of 
subsample 3 should have mild psychopathology including 
subclinical psychotic symptoms, as evidenced by a score of 
or above 6 on the PQ but are not at ultra-high risk (UHR) 
for psychosis, as indexed by the CAARMS. Finally, partic-
ipants of subsample 4 should be at UHR for psychosis, 
as indexed by the CAARMS. Exclusions criteria are: (1) 
a history of or current psychotic episode, according to 
the Diagnostic and Statistical manual of Mental Disor-
ders 4 (DSM-4) criteria, (2) significant hearing or visual 




To recruit subsample 1, the study will be announced at 
several university sites, public places in Groningen and 
social media (start recruitment: September 2015). Inter-
ested individuals can contact the researchers by phone 
or email for more information. They will then be sent 
an information letter, flyer, informed consent form and 
Figure 2 Flow chart. Note: light grey area within blue dashed square indicates optional measurements.
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the initial screenings questionnaires. After receiving 
the completed screening questionnaires and informed 
consent forms, the 25 (out of 100) individuals with the 
highest CAPE scores will be invited to participate in the 
main study (first inclusion: December 2015). For subsam-
ples 2–4, individuals will be recruited from mental health-
care institutions in four northern Dutch provinces (first 
inclusion: April 2016). To which subsample they will be 
recruited is determined using the instruments described 
under study population. For these sites where patients 
give their consent for receiving information about 
ongoing research projects, a package containing detailed 
information on the study (information letter and flyer), 
along with screening questionnaires and an informed 
consent form, will be sent to potential participants. Inter-
ested individuals can fill out and return requested forms 
(including informed consent form). After receiving 
the requested forms, an individual’s therapist will be 
consulted about several exclusion criteria. For these sites 
where participants do not give consent in advance, the 
individual’s clinical worker will be provided a package 
containing detailed information on the study (informa-
tion letter and flyer), along with screening questionnaires 
and an informed consent form. The clinical worker will 
prescreen his/her client on the exclusion criteria of the 
study and hand over the package if he/she fits the profile 
of the study. Study participants can continue their therapy 
and medical treatment as usual; they will be asked to 
register any changes in medication or treatment during 
the daily ambulatory assessments.
Screening
The information package that interested individuals 
receive contains an information letter, two screening 
questionnaires and an informed consent form. All poten-
tial participants can ask questions before completing 
the informed consent form or the screening question-
naires. As mentioned in the information letter, in case 
subjects decide to participate, they should fill out and 
send back these questionnaires and the informed consent 
form. This consent form covers the baseline ambulatory 
assessment period and the yearly follow-up assessments 
(three in total). On this consent form, permission will 
be asked to reinvite subjects for the follow-up ambula-
tory assessment period, for which they have to complete 
a separate consent form (1 year later). Also, permission 
will be asked to use data from the psychiatric case register 
of the north of the Netherlands. The first screening 
questionnaire is a screening questionnaire on general 
health, containing questions on demographics, health 
complaints (such as visual or hearing impairments), preg-
nancy, drug and alcohol use, medication use and mental 
health problems. This will be used to screen on exclusion 
criteria. The second screening questionnaire is the CAPE. 
This instrument is used to screen individuals recruited 
from the general population (subsample 1) on psychotic 
experiences but will be administered to all participants 
to enable group comparisons on the level of subclin-
ical psychotic experiences. The highest scoring quartile 
(n=25) will subsequently be included in the main study. 
Subjects will have 1 week to decide about participation.
Figure 3 Definition of subgroups. CAARMS, Comprehensive Assessment of At Risk Mental State; CAPE, Community 
Assessment of Psychic Experiences; Mirorr, Mapping Individual Routes of Risk and Resilience; PQ, Prodromal Questionnaire.
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Baseline interview and ambulatory assessments (year 1)
If subjects are eligible to enter the study and agree to 
participate, they will be invited (by telephone or email) 
for an introduction interview at the University Medical 
Centre Groningen. A few days before the interview, self-re-
port questionnaires will be administered via email (see 
data management for more information). The question-
naires assess symptomatology, functioning, clinical stage 
and factors of risk and resilience. During the interview, 
the study will be explained to them in detail, and a diag-
nostic psychiatric interview will be held. If in an excep-
tional case the participant does not possess a smartphone, 
this will be provided to the participant during the study 
period. An appointment for an end-of-study interview will 
be planned. Also, the participants will be asked to desig-
nate suitable moments at which the researcher can call 
him/her to inquire on the progression of the study and to 
help with any problems the participant may experience.
The participants then start completing the electronic 
daily diary for 3 months. Every evening, they receive a text 
message with a link that directs them to a web-based diary 
questionnaire in a secure environment. Measurements 
are always in the evening, asking about the past day; 
exact times can vary per person (but not per day) and 
are fixed according to the participant’s wishes. However, 
all participants have 24 hours between each measurement 
point. For example, participant A will always receive her 
text message at 22:00 and participant B always at 21:15. A 
window of 1.5 hours will be allowed to fill in the diary, and 
reminder messages will be send every half hour. Short 
questions will be presented on sequential screens, which 
are mainly answered using visual analogue scales. During 
the research period, participants are also provided a 
paper log, in which they can note any unusual events, 
start of or changes in medication use and problems they 
encounter with the research procedures. The researchers 
will telephone the participants six times during the study 
period (every other week) to motivate the participant, 
answer questions about the study procedures and provide 
technical help. They will also be available by telephone 
and email if participants need help at other moments.
During the end-of-ambulatory-assessment (3 months 
after baseline) interview participants will fill out an 
online questionnaire battery once more and report on 
any changes in medical treatment. Furthermore, they will 
also be asked to comment on the data collection and the 
study in general. We will use this information to check 
whether the study affected their thoughts and behaviours 
in any way, whether there had been special events that 
might have affected the data collected.
Follow-up assessments
All participants will receive questionnaires about func-
tioning and clinical stage via email 1, 2 and 3 years after 
baseline. The participants will be able to fill these in at 
home. Shortly after filling in the questionnaires, partic-
ipants will be interviewed by telephone or face to face 
at one of our research facilities, depending on their 
preferences, to establish the presence/absence of psychi-
atric disorders with a diagnostic interview. In addition, 
to distinguish individuals in clinical stage 1a from indi-
viduals in clinical stage 1b (all individuals with a score 
of 6 or higher on the PQ-16), data from the CAARMS 
interview is needed. Participants will be reminded about 
the follow-up assessments a few weeks before the actual 
follow-up by means of an information letter.
Follow-up ambulatory assessment period (year 2)
In the aforementioned information letter, participants 
will also read information about a second ambulatory 
assessment period that they can enrol in. If they are inter-
ested, they are invited for another introduction interview 
(given that they still fulfil the inclusion and exclusion 
criteria as evidenced by their answers to an online version 
of a general health questionnaire). This interview is 
similar to the introduction interview at baseline (ie, ques-
tionnaire battery and procedures). An exception is that 
questionnaires about symptomatology, functioning and 
clinical stage will not be administered, because they have 
been covered already by the usual follow-up assessments. 
Participants then start their second 3-month period of 
ambulatory assessments 1 year after the first diary period. 
The end of ambulatory assessment interview will take 
place, again with similar questionnaires to the one held 
at baseline.
Instruments
A complete overview of the instruments used throughout 
the study is presented in table 1.
Diary measures
The items assessed in the daily questionnaires will be used 
to model individual networks of symptoms, experiences 
and emotions. Items included in the dairy questionnaires 
were chosen from a transdiagnostic perspective and cover 
a broad range of feelings and experiences that are char-
acteristic for (subclinical) psychotic experiences, depres-
sion, anxiety, mania, obsessive compulsive behaviour and 
anger. These disorders are known for the co-occurrence 
of psychotic symptoms6 7 and comorbidity.48 For the 
complete item list, see online supplementary table 1.
Positive psychotic experiences can be divided into five 
categories, namely paranoia, delusions, hallucinations, 
megalomania and paranormal beliefs.74 Because para-
normal beliefs are often stable over time, we will include 
items covering the first four categories. Negative symp-
toms of psychosis will be covered by items about flattened 
affect (eg, anhedonia, low motivation and social with-
drawal), which resemble closely the negative symptoms 
of the CAPE. Most items are adopted from previous expe-
rience sampling method (ESM) studies,75–77 and all items 
are adapted for daily use.
Symptoms of depression will be measured using items 
that correspond closely to the Patient Health Question-
naire-9,78 a self-administered questionnaire for screening 
and measuring the severity of depression. Anxiety 
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symptoms will be measured using items that correspond 
closely to the Hospital Anxiety and Depression Scales – 
Anxiety.79 Mania, obsessive compulsive behaviour and 
anger are measured with items that correspond closely to 
items from the DSM-5—screener for the corresponding 
clinical disorders.80
Positive and negative mood states over the past day will 
be measured with 12 items from the circumplex model 
of affect.81 82 Momentary affect will be measured with 
an item for valence (‘I feel unpleasant – pleasant’) and 
activation (‘I feel aroused/activated – quiet/still’) at the 
beginning of each diary entry. Other items cover sleep, 
daily activities and situations that may influence psychi-
atric symptoms, such as positive and negative events, 
social interactions, coping behaviour, physical activity and 
drug use.
Follow-up measures
Important outcomes that are linked to the above 
described network characteristics are (progression 
through) clinical stages, functioning and need for care. 
Progression through clinical stages will be assessed with 
the PQ-16, the CAPE and the CAARMS, the Symptom 
Check List (SCL-90)83 and the Schedules for Clinical 
Assessment in Neuropsychiatry, short version.84 Social 
functioning will be assessed using the Groningse 
Vragenlijst voor Sociaal Gedrag85 and the Flourishing 
Scale.86 Need for care will be assessed using self-re-
ported information on care use. Additionally, need for 
care will be assessed by linking data from the psychiatric 
case registry to our sample when approved by the partic-
ipant (as stated on the informed consent form). Specifi-
cally, the frequency and type of care use throughout the 
study period will be obtained.
Assessments predaily and postdaily diary period(s)
Before and after the daily diary assessments, several 
questionnaires will be administered to assess symp-
tomatology, functioning and several risk and resil-
ience factors. Psychotic symptoms will be assessed with 
the CAPE, depression and anxiety symptoms with the 
Depression Anxiety and Stress Scale,87 mania symp-
toms with the Altman Self-Rating Mania Scale,88 social 
support with the Social Support List,89 resilience with 
the Brief Resilience Scale90 and coping style with the 
Utrechtse Coping Lijst.91 Furthermore, physical activity 
levels will be tracked with an accelerometer, the ActiCal 
(Respironics, Bend, Oregon, USA), during the first 
2 weeks of the second diary period. Output of this 
instrument will be presented as Energy Expenditure 
and Metabolic Equivalent of Task. The physical activity 
measurements are added to serve as a pilot study and 
are not obligatory.
At baseline, sleep habits will be assessed with the 
Munich Chronotype Questionnaire92 to optimise the 
diary assessment process. Also, potential confounders 
such as smoking, alcohol/drug consumption, socio-
economic status and body mass index will be registered 
by means of a general health questionnaire. In addi-
tion, stressful life events will be assessed, using the 
list of threatening experiences.93 Finally, pertaining 
to subgroup 4 only, social cognition will be assessed 
using the Faux Pas Task,94 and bonding with parents 
will be assessed with the Inventory of Parent and Peer 
Attachment.95 96 These factors may be of importance 
in determining a transition from an UHR status to 
psychosis.
data analysis plan
To map individual symptom networks of day-to-day 
symptom levels, multivariate time-series analysis will 
be employed on each individual’s time series data. 
Specifically, vector autoregression (VAR) models will 
be applied.97 These models are particularly suited for 
investigating the temporal dynamics between two or 
more variables. The resulting associations between 
symptoms will subsequently be presented as networks, 
and network parameters will be estimated. These 
include (but are not limited to) the strength and direc-
tionality of symptom connections (see figure 1) and 
centrality indices (information about the position of a 
symptom in the network). Next, symptom networks will 
be compared (1) across different subgroups of severity 
and (2) when the second diary period is completed, 
within each individual.
In addition, a data-driven approach will be used to 
identify individuals with similar symptom network char-
acteristics by (1) qualitative network comparison, (2) 
quantitative comparison of centrality indices98 99 and (3) 
longitudinal mixture models.100 These subgroups will 
then be compared on their levels of symptomatology 
and functioning and on course of symptomatology over 
time. Furthermore, the predictive value of the network 
parameters will be compared with the predictive value of 
usual predictors of illness course, namely cross-section-
ally assessed level of (subclinical) psychotic pathology. 
Specifically, sensitivity and specificity of these network 
characteristics can be compared with sensitivity and 
specificity of baseline subclinical levels of psychotic 
symptoms (CAPE) and general psychopathology (SCL-
90). Finally, risk and resilience factors, such as stressful 
events, social interactions, physical activity, coping and 
resilience, may also influence symptoms and, impor-
tantly, their dynamics in the network but may do so 
differently in individuals with good or poor clinical 
and functional outcome. The role of these factors will 
be addressed by including them in individual network 
analyses to examine their direct and indirect impact on 
symptomatology and each other.
To control for potential confounding effects of demo-
graphic factors, such as sex, age and social economic 
status, these variables will be added as covariates to all 
group level analyses.
Based on previous work,101 102 we expect no more 
than 10% missing data. Missing values will be imputed 
with expectation-maximisation imputation, following 
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special recommendations for time-series datasets.103 A 
(two-sided) P value of 0.05 is applied for statistical testing.
sample size and power
Within-person analyses: constructing individual symptom networks
Exact sample size calculations are not possible in studies 
using VAR, as it is typically unclear in such studies what 
effect size can be expected. This is because the direction 
of causality and the number of lagged influences in the 
system under investigation are usually unknown, and bidi-
rectional and feedback effects can be present as well.97 
However, as previous work from our group101 104 105 and 
work of others106 suggests, 60–90 measurements suffice to 
reliably identify reciprocal associations between multiple 
variables.
Between-person analyses: associating symptom networks to 
clinical stage
In the between-person analyses, the data have a multi-
level structure. Therefore, the unilevel equivalent of 
the multilevel sample size107 was taken to calculate the 
power, assuming a conservative intraclass correlation of 
0.8. Assuming differences of 0.05 in mean coefficients 
(SD=0.07) between the different groups,24 the proposed 
study has a power of 0.8 (to detect significant differences 
at P<0.05). Subgroups of n=25 are large enough to take 
into account effects of several covariates.108
Ethics and dissemination
The study will be conducted in accordance with the Decla-
ration of Helsinki, meaning that participation is voluntary 
and written informed consent will be obtained. Several 
protocols have been developed for situations where clin-
ical care may be warranted, for example, in case of disclo-
sure of suicidal thoughts or in case of UHR status in one 
of the lower risk groups.
An online outcome monitoring system, called RoQua 
(www. roqua. nl) is used for data collection and data 
storage, to which only designated researchers have 
access via the use of passwords combined with Google 
authentication. Participants have access to the question-
naires via a link in their email inbox. The safety of this 
system is guaranteed by the University Medical Center 
Groningen (UMCG) (an ‘In Control Statement‘ is avail-
able on request). Data management is also organised 
according to UMCG standards, including a strict sepa-
ration of identifying patient data (name, date of birth 
and so on) and the anonymous datasets available for 
the researchers.
Data gathering was not completed when this manuscript 
was submitted. After the study has ended and the study’s 
main results have been published, the data obtained by 
this study will become available on reasonable request. 
Requests should be sent to  j. t. w. wigman@ umcg. nl with 
the topic name MIRORR data. The results of the study 
will be published in (inter)national peer-reviewed jour-
nals, presented at research, clinical and general public 
conferences.
dIsCussIon
Current diagnostic systems are increasingly criticised by 
mental health professionals, researchers and users of 
mental healthcare.9 12 26 109 Conceptualisation of psycho-
pathology in terms of (1) clinical staging (at macro level) 
and (2) dynamic, individual symptom networks (at a more 
micro level), which is the purpose of this study, represents 
a promising avenue to tackle both scientific and clinical 
problems. From a scientific perspective, improving our 
understanding of the factors driving the development 
of psychopathology by investigating how symptoms 
influence each other will enhance our ability to identify 
valid phenotypes to predict onset of (psychotic) mental 
disorders and to link with other relevant information 
(eg, genetic or endophenotypic variation). From a clin-
ical perspective, a better understanding of why psychotic 
symptoms can lead to a need for care in some, but resolve 
spontaneously in others, will help mental health profes-
sionals to adequately recognise the early needs of individ-
uals who are likely to develop mental illness or functional 
impairments. This is important because interventions are 
both more effective and less invasive when applied early 
in the course of illness.22 In more progressive clinical 
stages, deeper knowledge of the dynamic ways symptoms 
impact on each other will help to differentiate between 
those likely to recover or to deteriorate and between 
those likely to be responsive or resistant to treatment. 
Using symptom networks will improve the application of 
individually tailored, person-based interventions, adapted 
to one’s current clinical stage and symptomatology, as 
different stages require different types of intervention. 
Since personalised interventions better fit individual 
needs, they will result in enhanced treatment response,110 
reducing the costs of mental disorders at both personal 
and societal level. Thus, the use of symptom networks 
will assist in improving and fine-tuning dynamic models 
of psychopathology, which will stimulate both clinical (in 
terms of both diagnostics and intervention) and scientific 
progress.
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